Montreal researchers part of international study of drug that could delay Alzheimer’s disease - CityNews Montreal
This story deserves to be shared
Send it to someone who'd care, or post it on your networks.
Researchers in Montreal are taking part in an international clinical trial testing whether a drug can delay the onset of Alzheimer’s symptoms in people who show biological signs of the disease but have not yet experienced memory or cognitive decline.
“We’re hoping to keep pushing the front here and eventually make Alzheimer’s much less of a societal concern than (it) is right now,” said Dr. Simon Ducharme, a neuropsychiatrist at the Douglas Mental Health University Institute.
This article is an excerpt. To read the full content, visit the original source. CityNews Montreal
Related articles
Continuous glucose monitors help type 2 diabetes patients spend 5 more hours a day in healthy blood sugar range - Medical Xpress
Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.
Wearing headphones during surgery may reduce nausea and vomiting afterward - Medical Xpress
Patients who wore noise-canceling headphones during minimally invasive gynecological surgery were significantly less likely to experience postoperative nausea and vomiting (PONV), suggest findings from a randomized clinical trial presented at the Anesthesiology 2026 annual meeting.
Kefah Mokbel: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? - Oncodaily
“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.
0 comments
No comments yet. Be the first to share your thoughts!